Strategic LDL-C focus Targeted opportunities exist for partnering with NewAmsterdam to advance CETP inhibitor obicetrapib as an adjunct therapy for patients intolerant or inadequately managed on statins, including those with ASCVD or familial hypercholesterolemia.

Late-stage momentum Leverage their late-stage development and ongoing phase 3 trials to position value propositions around improved LDL-C lowering, potential cardiovascular risk reduction, and differentiated oral, low-dose CETP therapy in the lipid-lowering landscape.

Strategic partnerships Opportunities to engage in collaborations for large-scale synthesis, manufacturing enablement, and potential co-development or licensing of obicetrapib and combination regimens with ezetimibe, supported by their recent industry collaborations.

Commercial readiness Prepare for market access and payer discussions by aligning on demonstrated revenue potential, competitive positioning against statins and other lipid-lowering agents, and the ability to address unmet needs in high-risk LDL-C populations.

Funding and growth Capitalize on substantial funding and investor activity to propose joint development or strategic investment opportunities, leveraging their revenue trajectory and strong funding runway to accelerate clinical and regulatory milestones.